Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Explore NIH Funding Opportunities at RESI Boston Conference!

24 Aug

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

We are excited to announce an exclusive workshop that will be a pivotal highlight of the RESI Boston Conference, happening from September 18-20. Join us and unlock the door to non-dilutive grant funding for your early-stage health innovations

Workshop Topic: Leveraging NIH’s Non-Dilutive Grant Funding

Date: September 18th Time: 11:00 AM ET Location: Boston Park Plaza

Workshop Description

The NIH helps US-based small businesses in their early stages by offering over $1.3 billion in R&D funding through various programs. Small businesses can use NIH funding to generate proof-of-concept data, de-risk their innovation, and attract partners and investors to commercialize their innovation. We support a range of high-impact technologies, such as research tools, diagnostics, digital health, drugs, medical devices, and more. The NIH’s grants do not require equity and can provide the initial funding you need to translate your scientific innovations from an idea to a product. On this panel, representatives of the National Institute on Aging and the National Institute of General Medical Sciences will discuss how to apply for NIH funding, NIH-funded programs and entrepreneurial hubs which support founders across the nation, and unique priority areas in disease areas like Alzheimer’s disease and dementia.

Meet the Panelists

We are happy to introduce the speakers from the NIH who will provide a comprehensive overview of the relevant programs and their requirements:

Eddie Billingslea Joshua HOOKS Rajesh Kumar
Eddie Billingslea
Small Business Strategy Coordinator
National Institute on Aging
Joshua HOOKS
Program Officer
National Institute on Aging
Rajesh Kumar
Program Officer
National Institute on Aging

Get Registered for RESI Boston Conference

This workshop is an opportunity for attendees registered for the RESI Boston September conference. If you haven’t already, register now for RESI to gain access to this invaluable workshop and a multitude of other networking and learning opportunities.

Visit the NIA Exhibit Table

While at the conference, we encourage you to explore the NIA exhibit table. Engage with the experts directly, discover more about NIH Small Business Programs, and explore the vast potential for collaboration and innovation in aging-related research and development.

National Institute on Aging (NIA)

The National Institute on Aging’s (NIA) Small Business Programs manage the largest source of early-stage funding for aging-related R&D. With an annual budget of over $140 million, NIA provides R&D grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Our mission is to develop interventions that prevent or treat Alzheimer’s disease (AD) and AD-related dementias, and we are committed to driving innovation in this critical field.

Join us at the RESI Boston Conference on September 18th at 11:00 AM ET and embark on a transformative journey into the world of non-dilutive grant funding, innovation, and collaboration. Register to meet NIA team and 300+ life science investors to unlock the potential of your health innovations.

Should you have any questions or require further information, please don’t hesitate to contact us at resi@lifesciencenation.com.

We look forward to welcoming you to this exciting event!

RESI-Boston-2023-September-1100px-w

Announcing Family Office BioForum at RESI Boston September 2023

17 Aug

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

RESI Boston September will feature the Family Office BioForum, for both sourcing assets and identifying syndication partners bridging the gap between family offices and investment opportunities within the life sciences sector. The Family Office BioForum will feature an open-to-the-public Family Office Panel as part of the RESI program and an invitation-only luncheon discussing early-stage investment topics, including souring technology assets, identifying syndicate opportunities, and finding the right investment funds.

As the life sciences sector continues to burgeon with groundbreaking discoveries, therapies, and technologies, the need for early capital injection becomes ever more pronounced. The Family Office BioForum is a convergence point where family offices can simultaneously identify promising startups and collaborate with other like-minded investors.

The Power of Syndication

Syndication has emerged as a dynamic strategy in the investment landscape, offering distinct advantages to family offices and entrepreneurs seeking funding. Family offices can diversify risk and share due diligence efforts by joining forces with other investors in a syndicate. This collaborative approach allows investors to tap into a broader range of investment opportunities and capitalize on their combined expertise. Conversely, entrepreneurs benefit from access to a syndicate’s collective knowledge and resources, expediting fundraising and enhancing their chances of securing the necessary funds.

The Family Office Factor

Family offices are known for their long-term investment outlook and commitment to fostering meaningful impact. With a mission to preserve and grow their wealth across generations, family offices are uniquely positioned to contribute to the life sciences sector. Their involvement goes beyond monetary support; it encompasses mentorship, guidance, and a vested interest in the success of the ventures they invest in. The Global Family Office BioForum acknowledges this distinctive role and seeks to create an environment where family offices can connect with like-minded syndicate partners and explore transformative investment opportunities.

For more information on the Family Office BioForum Click here
If you are a Family Office and would like to attend the Family Office BioForum Luncheon Click here

RESI-Boston-2023-September-1100px-w

Partnering Opens for RESI Boston Next Week

17 Aug

By Karen Deyo, Director of Product, Israel BD, LSN

Partnering for RESI Boston September, a hybrid event (in-person on September 18, or virtually on September 19-20) launches next Monday, giving registered attendees access to RESI’s unique partnering platform. This platform allows attendees to filter search results with a high degree of precision.

At RESI, unlike other conferences, requesting a meeting with an investor does not require a company to spend most of the initial meeting finding out if they are a fit for the investor or not. Companies can easily determine a list of investors who are interested in their sector, indication, and stage of development before requesting a meeting. Investor profiles are written by Life Science Nation (LSN)’s Investor Research team in a phone interview with each investor, as a requirement before registration.

The RESI Partnering Platform has an integrated video conferencing system, allowing companies to simply log in to the platform and initiate their meetings through their schedule. Make sure to look at the tutorial video below, to see all the features offered by our system!

Premier-Mandates

Premier Platform Sample

Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!

Partnering_Tutorial_Webinar

RESI-Boston-2023-September-1100px-w

LSN Announces Collaboration with Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at RESI Boston in September

17 Aug

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.

As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:

  1. Nutrition
  2. Polyphenols to treat chronic diseases
  3. Robotic intramuscular injections
  4. Wearable artificial kidney for ambulatory dialysis
  5. Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
  6. Electronic medical records
  7. Non-viral and re-dosable gene therapies

Ontario Companies

These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.

With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!

RESI-Boston-2023-September-1100px-w

Surge in Family Offices: Investing in Healthcare

10 Aug

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.

LSN Collaboration with Stetson Family Office in 2019

LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities.  This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.

The Dynamics of Family Offices

Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million.  This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.

Why Healthcare?

As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals.   The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.

Balancing Profit and Purpose

Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.

Driving Innovation

One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.

RESI-Boston-2023-September-1100px-w

Announcing the Global Partnering Campaign, LSN’s Newest Product

10 Aug

By Karen Deyo, Director of Product, Israel BD, LSN

Life Science Nation (LSN) is excited to announce that our newest product, the Global Partnering Campaign Salesforce App, is live! This is a new way to access the LSN Investor and Licensing Partner Database, taking the benefits of LSN’s curated data (10 categories of investors from 3,000 firms with 10,000 contacts), and combining it with LSN’s custom-developed fundraising campaign management tool.

What is the difference between the LSN Investor and Licensing Partner Database and the new GPC product?

The GPC product is a Salesforce App that has to be downloaded off of the Salesforce AppExchange and installed into the company’s Salesforce account. The LSN Investor and Licensing Partner Database gives you access to the same content without a subscription to Salesforce.

Do I need to subscribe to Salesforce to use the new GPC product?

Yes, this new product is available through Salesforce only. Using a CRM like Salesforce is a crucial tool for managing a fundraising campaign and tracking all of your contact with investors and licensing partners – ensuring no missed opportunities or dropped balls.

What do I need to do to get the GPC App?

If you are not already a Salesforce client, subscribe to Salesforce (Professional license or above required), go the Salesforce AppExchange, and find and install the Life Science Nation – Global Partnering Campaign (GPC) app. Once you have installed the app, you will need to subscribe to the Essential or Premium plan through this link and contact LSN at gpc@lifesciencenation.com for your onboarding with your BD representative. After the onboarding is complete, LSN staff will activate the GPC app, and you can start identifying your Global Target List of investors and licensing partners and begin your outreach!

Click here to watch a demo of the new product!

RESI-Boston-2023-September-1100px-w

Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences (CLS)

10 Aug
Shikha-SharmaShikha Sharma Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to California Life Sciences.

Shikha Sharma (SS): California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.

CD: What type of companies do California Life Sciences consider for membership?

SS: CLS members represent companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.

CD: What stage of fundraising is California Life Sciences looking to support?

SS: The CLS Innovation & Entrepreneurship programs primarily support early-stage companies in fundraising stages from pre-seed to Series A. However, the broader CLS community encompasses members, companies, stakeholders, and pharma industry professionals with accessibility to later stage fundraising know-how and connections. Becoming part of CLS gives you access to a broad network that can directly and indirectly support companies in any stage of fundraising.

CD: Clearly, California Life Sciences, is in California. Though, not all your members are located in California. What are your geographic qualifications?

SS: We don’t have geographic qualifications, per se.  CLS welcomes any organization that is looking to access, expand and/or maintain a foothold in what I would consider the most robust life sciences ecosystem worldwide.

CD: What works well for California Life Sciences in being a part of the RESI experience?

SS: As part of our portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid our members in the fundraising journeys. Importantly, opportunities like RESI connects them with Seed and Series B investors, channel and licensing partners.

CD: What other information is important for companies to consider about California Life Sciences?

SS:  California Life Sciences’ innovation and entrepreneurship initiatives connect life science startups to the resources needed to help them effectively scale their ventures. Our programs create a platform for accessing business partners, investors, foundations and patient advocacy organizations, peers, and other industry leaders.

Designed to nurture and advocate for emerging and diverse innovators from throughout the state, CLS offers advisory services, positioning for capital tools, access to capital through strategic partnerships and events and US market access resources to help in the development and commercialization of their business.

RESI-Boston-2023-September-1100px-w